LYTIR

Company · NAMS

NewAmsterdam Pharma Company N.V.

Name as listed on its exchange; filed with the SEC as NewAmsterdam Pharma Co N.V.

Nasdaq's symbol directory lists NAMS on Nasdaq as “NewAmsterdam Pharma Company N.V. - Ordinary Shares”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($226K); insiders sold on 5 occasions ($9.1M); 3 filings by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $226K in total; Insider sales: $9.1M in total.Jun: Insider sales $1.2MJul: Insider sales $3.2MAug: Insider sales $3.4MSep: Insider purchases $226KSep: Insider sales $1.3MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $226KInsider sales below: $9.1M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Johannes Jacob Pieter Kastelein, Chief Scientific Officer sold on 2 days all under a 10b5-1 plan latest Sep 30, 2026 sold $4.6M
  2. Louise Frederika Kooij, Chief Accounting Officer sold on 2 days all under a 10b5-1 plan latest Jul 20, 2026 sold $4.4M
  3. Michael H. Davidson, Chief Executive Officer bought on 1 day latest Sep 14, 2026 bought $226K
  4. Smither John W sold on 1 day latest Sep 4, 2026 sold $41K
Every trade (6)
  1. SELLJohannes Jacob Pieter Kastelein, Chief Scientific Officer sold Sep 30, 2026 50,246 shares 10b5-1 plan (scheduled) filing $1.3M
  2. BUYMichael H. Davidson, Chief Executive Officer bought Sep 14, 2026 10,000 shares filing $226K
  3. SELLSmither John W sold Sep 4, 2026 1,600 shares filing $41K
  4. SELLJohannes Jacob Pieter Kastelein, Chief Scientific Officer sold Aug 24, 2026 125,000 shares 10b5-1 plan (scheduled) filing $3.4M
  5. SELLLouise Frederika Kooij, Chief Accounting Officer sold Jul 20, 2026 105,000 shares 3 legs combined 10b5-1 plan (scheduled) filing $3.2M
  6. SELLLouise Frederika Kooij, Chief Accounting Officer sold Jun 22, 2026 40,000 shares 2 legs combined 10b5-1 plan (scheduled) filing $1.2M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. FMR LLC filed Nov 5, 2026 Schedule 13G/A passive 11,941,763 shares filing 10%
  2. Frazier Life Sciences X, L.P. filed Sep 22, 2026 Schedule 13D/A may seek influence 10,424,224 shares filing 8.7%
  3. FMR LLC filed Aug 6, 2026 Schedule 13G/A passive 10,339,663 shares filing 8.8%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Financial statements and exhibits filing Nov 4, 2026
  2. Other events filing Sep 29, 2026
  3. Other events filing Sep 21, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.